Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment

Autores
Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo
Año de publicación
2018
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment.
Fil: Armando, Romina Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina
Fil: Mengual Gómez, Diego Luis. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Juritz, Ezequiel Ivan. Universidad Andrés Bello; Chile
Fil: Lorenzano Menna, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
CANCER
DKC1
HTR
INHIBITORS
TELOMERASE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/98541

id CONICETDig_fdf0630c7afe2e8dc26271c636a0d795
oai_identifier_str oai:ri.conicet.gov.ar:11336/98541
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatmentArmando, Romina GabrielaMengual Gómez, Diego LuisJuritz, Ezequiel IvanLorenzano Menna, PabloGomez, Daniel EduardoCANCERDKC1HTRINHIBITORSTELOMERASEhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment.Fil: Armando, Romina Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; ArgentinaFil: Mengual Gómez, Diego Luis. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Juritz, Ezequiel Ivan. Universidad Andrés Bello; ChileFil: Lorenzano Menna, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; ArgentinaFil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaMolecular Diversity Preservation International2018-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/98541Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo; Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 19; 10; 10-2018; 1-161422-0067CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/19/10/3216info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms19103216info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T14:49:41Zoai:ri.conicet.gov.ar:11336/98541instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 14:49:41.591CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
title Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
spellingShingle Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
Armando, Romina Gabriela
CANCER
DKC1
HTR
INHIBITORS
TELOMERASE
title_short Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
title_full Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
title_fullStr Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
title_full_unstemmed Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
title_sort Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment
dc.creator.none.fl_str_mv Armando, Romina Gabriela
Mengual Gómez, Diego Luis
Juritz, Ezequiel Ivan
Lorenzano Menna, Pablo
Gomez, Daniel Eduardo
author Armando, Romina Gabriela
author_facet Armando, Romina Gabriela
Mengual Gómez, Diego Luis
Juritz, Ezequiel Ivan
Lorenzano Menna, Pablo
Gomez, Daniel Eduardo
author_role author
author2 Mengual Gómez, Diego Luis
Juritz, Ezequiel Ivan
Lorenzano Menna, Pablo
Gomez, Daniel Eduardo
author2_role author
author
author
author
dc.subject.none.fl_str_mv CANCER
DKC1
HTR
INHIBITORS
TELOMERASE
topic CANCER
DKC1
HTR
INHIBITORS
TELOMERASE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment.
Fil: Armando, Romina Gabriela. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina
Fil: Mengual Gómez, Diego Luis. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Juritz, Ezequiel Ivan. Universidad Andrés Bello; Chile
Fil: Lorenzano Menna, Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Gomez, Daniel Eduardo. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología. Laboratorio de Oncología Molecular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Immortality is one of the main features of cancer cells. Tumor cells have an unlimited replicative potential, principally due to the holoenzyme telomerase. Telomerase is composed mainly by dyskerin (DKC1), a catalytic retrotranscriptase (hTERT) and an RNA template (hTR). The aim of this work is to develop new inhibitors of telomerase, selecting the interaction between hTR–DKC1 as a target. We designed two models of the human protein DKC1: homology and ab initio. These models were evaluated by different procedures, revealing that the homology model parameters were the most accurate. We selected two hydrophobic pockets contained in the PUA (pseudouridine synthase and archaeosine transglycosylase) domain, using structural and stability analysis. We carried out a docking-based virtual screen on these pockets, using the reported mutation K314 as the center of the docking. The hDKC1 model was tested against a library of 450,000 drug-like molecules. We selected the first 10 molecules that showed the highest affinity values to test their inhibitory activity on the cell line MDA MB 231 (Monroe Dunaway Anderson Metastasis Breast cancer 231), obtaining three compounds that showed inhibitory effect. These results allowed us to validate our design and set the basis to continue with the study of telomerase inhibitors for cancer treatment.
publishDate 2018
dc.date.none.fl_str_mv 2018-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/98541
Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo; Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 19; 10; 10-2018; 1-16
1422-0067
CONICET Digital
CONICET
url http://hdl.handle.net/11336/98541
identifier_str_mv Armando, Romina Gabriela; Mengual Gómez, Diego Luis; Juritz, Ezequiel Ivan; Lorenzano Menna, Pablo; Gomez, Daniel Eduardo; Homology model and docking-based virtual screening for ligands of human dyskerin as new inhibitors of telomerase for cancer treatment; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 19; 10; 10-2018; 1-16
1422-0067
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/19/10/3216
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms19103216
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Molecular Diversity Preservation International
publisher.none.fl_str_mv Molecular Diversity Preservation International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1874774735244492800
score 13.334379